Jon Cousin

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Cooley advised Alto Neuroscience, a company pioneering precision psychiatry by developing targeted medicines designed to help patients get better faster, on its oversubscribed $45 million Series C financing round.

Cooley advised Secura Bio on intellectual property diligence matters surrounding its acquisition of global rights to Farydak from Novartis. Farydak is a prescription medication used to treat patients who have received prior treatment for multiple myeloma, a cancer that forms malignant plasma cells in the bone marrow.

“We are very pleased to acquire worldwide rights to Farydak as we execute our plan to aggressively build a meaningful, worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio. “Farydak will be a critical cornerstone of our strategy, as it offers a potentially valuable and high-growth treatment option for physicians in their therapeutic regimen for multiple myeloma patients when combined with a variety of other multiple myeloma therapies.”

Cooley advised Secura Bio on intellectual property diligence matters surrounding its $311 million acquisition ($70 million upfront and $241 million in milestones) of global rights to Copiktra. Copiktra is a prescription oncology medication used to treat patients who have received prior treatment for certain types of cancer, such as chronic lymphocytic leukemia and small lymphocytic lymphoma.

“Completing the Copiktra acquisition represents a major step in building our worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio.